Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Harvard Business School
QuintilesIMS
Fuji
Cipla
Queensland Health
Colorcon
Cantor Fitzgerald
Fish and Richardson

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,084,853

« Back to Dashboard

Which drugs does patent 9,084,853 protect, and when does it expire?

Patent 9,084,853 protects ADLYXIN and is included in one NDA.

This patent has twenty patent family members in fourteen countries.
Summary for Patent: 9,084,853
Title:Drive mechanism for a drug delivery device and drug delivery device
Abstract: A lead screw, a lead screw nut and a drive member are aligned with an axis. A coupling between the lead screw and the lead screw nut allows a helical movement of the lead screw. The drive member is rotationally locked with the lead screw nut. The lead screw is coupled with the drive member to generate a helical movement of the lead screw when the drive member is moved in one axial direction. The coupling is overridden when the drive member is moved in the opposite axial direction. Spline features are arranged on the lead screw in a row parallel to the axis with alternatingly small and large gaps between succeeding spline features. A stop feature of the drive member has a dimension in the direction of the axis which is larger than the small gaps and at most as large as the large gaps.
Inventor(s): Plumptre; David Aubrey (Worcestershire, GB)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE)
Application Number:13/825,813
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

Drugs Protected by US Patent 9,084,853

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-001 Jul 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-002 Jul 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,084,853

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10186735Oct 6, 2010
11153481Feb 7, 2011
PCT Information
PCT FiledOctober 05, 2011PCT Application Number:PCT/EP2011/067417
PCT Publication Date:April 12, 2012PCT Publication Number: WO2012/045793

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
Farmers Insurance
Colorcon
Merck
UBS
McKinsey
Chinese Patent Office
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.